Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

References

• Junlén HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29(3):668–676.
   PubMed Web of Science ®Google Scholar
• Mozas P, Nadeu F, Rivas-Delgado A, et al. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer J. 2020;10(3):31.
   PubMed Web of Science ®Google Scholar
• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1–2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981–987.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Luminari S, Barr PM, et al. Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologist. 2019;24(11):e1236–e1250.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83–v90.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Kondo E, Ogura M, Kagami Y, et al. Assessment of prognostic factors in follicular lymphoma patients. Int J Hematol. 2001;73(3):363–368.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Aschebrook-Kilfoy B, Chiu BCH, et al. The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras. Am J Hematol. 2014;89(6):633–638.
   PubMed Web of Science ®Google Scholar
• Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Blood. 2000;95:783–789.
   PubMed Web of Science ®Google Scholar
• Riihijärvi S, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol. 2011;86(2):124–128.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Byrtek M, Rai A, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85–95.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Zhou X, Day BM, et al. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016;91(8):770–775.
   PubMed Web of Science ®Google Scholar
• Provencio M, Royuela A, Torrente M, et al. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group. Cancer. 2017;123(19):3709–3716.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Shou Y, Bell JA, et al. Treatment patterns and survival outcomes in patients with follicular lymphoma: a 2007 to 2015 humedica database study. Clin Lymphoma, Myeloma Leuk. 2019;19(4):e172–e183.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202–1208.
   PubMed Web of Science ®Google Scholar
• Eurostat the statistical office of the EU. Life expectancy by age and sex [Internet]. Eurostat, Stat. Off. Eur. Union; 2020 [cited 2020 May 18]. Available from: https://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=sdg_03_10&plugin=1.
   Google Scholar
• Jäger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–1438.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MHJ, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119(14):3276–3284.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123(5):640–646.
   PubMed Web of Science ®Google Scholar
• Nelson BRA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate- or high-grade B-cell non-hodgkin's lymphoma in women. J Clin Oncol. 2001;19(5):1381–1387.
   PubMed Web of Science ®Google Scholar
• Ladikou EE, Kassi E. The emerging role of estrogen in B cell malignancies. Leuk Lymphoma. 2017;58(3):528–539.
   PubMed Web of Science ®Google Scholar
• Yakimchuk K, Iravani M, Hasni MS, et al. Effect of ligand-activated estrogen receptor Β on lymphoma growth in vitro and in vivo. Leukemia. 2011;25(7):1103–1110.
   PubMed Web of Science ®Google Scholar
• Talaber G, Yakimchuk K, Guan J, et al. Inhibition of estrogen biosynthesis enhances lymphoma growth in mice. Oncotarget. 2016;7(15):20718–20727.
   PubMedGoogle Scholar
• Kane EV, Bernstein L, Bracci PM, et al. Postmenopausal hormone therapy and non-hodgkin lymphoma: a pooled analysis of interlymph case-control studies. Ann Oncol. 2013;24(2):433–441.
   PubMedGoogle Scholar
• Yakimchuk K, Hasni MS, Guan J, et al. Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists. Blood. 2014;123(13):2054–2061.
   PubMed Web of Science ®Google Scholar
• Pierdominici M, Maselli A, Locatelli SL, et al. Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy. Oncotarget. 2017;8(5):8522–8535.
   PubMedGoogle Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Progress in advanced-stage follicular lymphoma. J Clin Oncol. 2018;36(23):2363–2365.
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122.
   PubMed Web of Science ®Google Scholar
• O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of Follicular Lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126–3129.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Sancho JM. Current prognostic and predictive factors in follicular lymphoma. Ann Hematol. 2018;97(2):209–227.
   PubMed Web of Science ®Google Scholar